Navigating CMC constraints during clinical development
Watch the replay/--/uploads/2026/02/ls-webinar-ACImmune-B-1.png)
What You’ll Learn In This Webinar
AC Immune and the neurodegenerative landscape :
Learn how proactive scenario planning helps teams anticipate constraints earlier, and turn cross-functional tension into faster, better decisions.
Scenario 1: Drug product switch during ongoing recruitment
- Compare the implications of switching DP within patient treatment schedules versus adapting recruitment to keep patients on a single DP process.
- Reveal the operational trade-offs behind each path, from supply continuity to patient scheduling and trial integrity.
- See how early constraint visibility supports decisions.
Scenario 2: Late-stage strategy and the shift to late-stage CMOs
- Understand why moving to late-stage CMOs often introduces hidden complexity, longer timelines, and cost escalation.
- Anticipate capacity, tech transfer, and manufacturing readiness constraints before they impact your clinical strategy.
- Bring late-stage considerations into trial design early, without slowing down execution.
What this enables: discover how N-SIDE helps create a win-win between Clinical and CMC teams by making interdependencies explicit, aligning plans earlier, and enabling faster, more resilient execution.
Live Q&A
Speakers
/--/uploads/2025/09/LVE.png)
Laurent Verdickt
Strategic Account Manager
/--/uploads/2026/02/Screenshot-2026-02-03-at-15.11.53.png)
Natalia Monini Bonini
Drug Product MSAT Assistant at AC Immune
/--/uploads/2026/02/1589527291040.jpeg)
Camille Martin
DS&SM MSAT Scientist at AC Immune
